T. Rowe Price Associates
NGNE icon

T. Rowe Price Associates’s Neurogene NGNE Stock Holding History

T. Rowe Price Associates’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-123,291
Closed -$2.82M – 3064
2024
Q4 		$2.82M Buy
+123,291
New +$4.59M ﹤0.01% 1483
2022
Q4 		– Sell
-1,015
Closed -$13K – 2963
2022
Q3 		$13K Hold
1,015
– – ﹤0.01% 2931
2022
Q2 		$21K Sell
1,015
-157
-13% -$3.83K ﹤0.01% 2926
2022
Q1 		$44K Buy
1,172
+370
+46% +$21.6K ﹤0.01% 2934
2021
Q4 		$77K Sell
802
-5
-0.6% -$609 ﹤0.01% 2899
2021
Q3 		$117K Sell
807
-970
-55% -$149K ﹤0.01% 2820
2021
Q2 		$328K Buy
1,777
+247
+16% +$54.6K ﹤0.01% 2560
2021
Q1 		$377K Buy
1,530
+526
+52% +$134K ﹤0.01% 2487
2020
Q4 		$283K Buy
1,004
+337
+51% +$82.3K ﹤0.01% 2442
2020
Q3 		$160K Buy
+667
New +$162K ﹤0.01% 2468
2019
Q4 		– Sell
-20,196
Closed -$1.15M – 2545
2019
Q3 		$1.15M Buy
+20,196
New +$1.23M ﹤0.01% 1754
2018
Q3 		– Sell
-67,500
Closed -$3.58M – 2595
2018
Q2 		$3.58M Sell
67,500
-119,250
-64% -$31.1M ﹤0.01% 1481
2018
Q1 		$52.6M Buy
186,750
+17,993
+11% +$4.97M 0.01% 850
2017
Q4 		$39.7M Sell
168,757
-25
-0% -$5.86K 0.01% 955
2017
Q3 		$47.9M Sell
168,782
-35
-0% -$10K 0.01% 861
2017
Q2 		$47.5M Sell
168,817
-35
-0% -$10K 0.01% 842
2017
Q1 		$56.4M Sell
168,852
-1,168
-0.7% -$410K 0.01% 779
2016
Q4 		$56.1M Buy
170,020
+7,052
+4% +$1.9M 0.01% 775
2016
Q3 		$43.5M Buy
+162,968
New +$32.9M 0.01% 856

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

T. Rowe Price Associates's NGNE Position: Q1 2025 in Review

T. Rowe Price Associates sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 123,291 shares — an estimated $2.82M sold.

T. Rowe Price Associates first reported a position in NGNE in Q3 2016 and held it in 19 quarters. The position peaked at $56.4M in Q1 2017. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • T. Rowe Price Associates reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 123,291 Neurogene shares in Q1 2025, an estimated $2.82M.
  • T. Rowe Price Associates first reported a position in Neurogene in Q3 2016 and held it in 19 quarters.
  • T. Rowe Price Associates's Neurogene position peaked at $56.4M in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.